PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27614128-0	2016	Pioglitazone inhibits EGFR/MDM2 signaling-mediated PPARgamma degradation.	Pioglitazone	0-12	epidermal growth factor receptor	Homo sapiens	22-26	
8679718-0	1996	Pioglitazone attenuates the inhibitory effect of phorbol ester on epidermal growth factor receptor autophosphorylation and tyrosine kinase activity.	Pioglitazone	0-12	epidermal growth factor receptor	Homo sapiens	66-98	
8679718-1	1996	A new anti-diabetic drug, pioglitazone, was tested as to whether it could ameliorate the decreased kinase activity of epidermal growth factor (EGF) receptor induced by phorbol ester (PMA) in A431 cells.	Pioglitazone	26-38	epidermal growth factor receptor	Homo sapiens	118-156	
8679718-6	1996	These results suggest that pioglitazone may act as a specific antagonist to the inhibitory effect by protein kinase C on the EGF receptor tyrosine kinase.	Pioglitazone	27-39	epidermal growth factor receptor	Homo sapiens	125-137	
27614128-5	2016	Therefore, our study revealed a novel mechanism that pioglitazone inhibited EGFR/MDM2-mediated cancer cell chemoresistance, which provides a novel strategy for cancer treatment.	Pioglitazone	53-65	epidermal growth factor receptor	Homo sapiens	76-80	
23370527-8	2013	The PPARgamma and EGFR interaction was determined by chromatin immunoprecipitation assay, and the effect of pioglitazone on EGFR activation by luciferase assay.	Pioglitazone	108-120	epidermal growth factor receptor	Homo sapiens	124-128	
23370527-9	2013	RESULTS: PTCs exposed to both high glucose and pioglitazone increased protein abundance of P-EGFR, NHE3, AQP1 and PPARgamma.	Pioglitazone	47-59	epidermal growth factor receptor	Homo sapiens	93-97	
23370527-13	2013	Pioglitazone induced PPARgamma binding to the EGFR promoter and subsequent downstream activation.	Pioglitazone	0-12	epidermal growth factor receptor	Homo sapiens	46-50